Phosphocitrate and its analogue N-sulpho-2-amino tricarballylate inhibit aortic calcification.
This study reports the ability of phosphocitrate and its enzyme-resistant analogue N-sulpho-2-amino tricarballylate to inhibit aortic calcification. Dystrophic calcification of aorta was induced by transplanting fresh aortic segments in Millipore chambers to the peritoneal walls of recipient rats. Daily intraperitoneal injection of the new inhibitors remarkably reduced calcium accumulation by the aortae and prevented the appearance of hydroxyapatite-like crystalline structures. Phosphocitrate was the most effective of the anti-calcifying agents tested, preventing aortic calcification at 1 mumole/day/rat. N-sulpho-2-amino tricarballylate was less effective, reducing aortic calcification by 60% at 10 mumoles/day/rat. The new inhibitors might prove therapeutically useful in man to arrest soft tissue calcification.
D000818:Animals; D001012:Aorta, Abdominal / Q000473:pathology; D001013:Aorta, Thoracic / Q000187:drug effects; D001018:Aortic Diseases / Q000473:pathology / Q000517:prevention & control*; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control; D002114:Calcinosis / Q000473:pathology / Q000517:prevention & control*; D002951:Citrates / Q000494:pharmacology*; D004577:Electron Probe Microanalysis; D008297:Male; D008854:Microscopy, Electron; D051381:Rats; D011919:Rats, Inbred Strains; D014233:Tricarboxylic Acids / Q000494:pharmacology*
D002951:Citrates; D014233:Tricarboxylic Acids; C014148:phosphocitrate; C039013:N-sulfo-2-aminotricarballylate